← GSK overview

GSK vs Bristol-Myers Squibb: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GSK plc (GSK.LSE)

Q3 2026
▲2▼2

GSK's new drug wins offset pipeline setbacks and legal risks

  • FDA approval of Jiditro and other regulatory wins GSK won FDA approval for Jiditro, its first lung cancer drug, plus regulatory nods for Jemperli and Hibsago. These expand GSK's oncology and specialty portfolios, offering new sales streams.

    New drug approvals are major positive catalysts for future revenue.

  • Strong Q2 results and cost-savings plan GSK reported 5% sales growth in Q2, raised full-year guidance, and announced a £1.9bn cost-savings plan. Specialty Medicines grew 14%, showing core business strength and efficiency gains.

    Financial performance and cost cuts directly boost investor confidence.

  • Pipeline setback and legal threat GSK dropped camlipixant, a potential £2.5bn product, and faces AnaptysBio's lawsuit over Jemperli rights. These create uncertainty about future revenue and legal costs.

    Pipeline failures and litigation are key negative drivers for the stock.

  • Competition and patent cliff concerns Moderna's mRNA flu vaccine challenges GSK's flu franchise, and the dolutegravir HIV patent cliff looms around 2028–29, threatening £2.74bn in H1 2026 sales. Vaccine restructuring cuts 641 Dresden jobs.

    Competitive threats and patent expirations weigh on long-term growth outlook.

September 2026
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

Latest
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

August 2026
▲3▼1

GSK rises on cost cuts, new drug wins, but Moderna threat looms

  • Cost-savings plan and UK investment GSK announced a £1.9bn cost-savings plan to fund late-stage trials, a £400m UK investment, and a new Cambridge R&D hub. This signals efficiency and commitment to innovation, boosting investor confidence.

    This is a major new financial and strategic initiative that drove shares up.

  • Strong Q2 results and raised sales guidance Q2 profit beat expectations, with sales up 5% to over £8.4bn and raised sales guidance. Although EPS guidance was cut on Nuvalent-related interest costs, the overall beat and sales outlook lifted shares.

    Quarterly earnings are a key driver of stock performance and provided positive surprises.

  • Regulatory wins for Jemperli and Hibsago FDA priority review for Jemperli in rectal cancer and world's first approval of Hibsago, a hepatitis B cure, plus Phase III progress for GSK's mRNA flu vaccine, lifted shares on pipeline strength.

    These regulatory milestones represent new growth opportunities and validate GSK's R&D.

  • Moderna's mRNA flu vaccine threat Moderna's FDA-approved mRNA flu vaccine directly threatens GSK's leading flu franchise, potentially pressuring future sales. This competitive threat is a new headwind for GSK.

    It introduces a significant competitive risk that could undermine a key revenue stream.

▲2▼1

GSK pipeline wins and cost cuts drive gains, Moderna flu threat weighs

  • Jemperli priority review for rectal cancer The FDA accepted GSK's Jemperli for priority review in locally advanced rectal cancer, with a decision expected by February 2027. Positive trial data showed patients had no detectable cancer for at least a year. This raises hopes for a new revenue stream and lifts the shares.

    A new regulatory milestone for a key cancer drug adds to GSK's growth outlook.

  • Moderna's mRNA flu vaccine approval Moderna won FDA approval for the first mRNA flu vaccine, for adults 50 and over, directly challenging GSK's flu vaccine business. While uptake depends on pricing and pharmacy stocking, it introduces a new competitor in a market GSK has long led, which could pressure future sales and the share price.

    This is a competitive threat to GSK's established flu vaccine franchise.

  • Hepatitis B cure and mRNA flu advance GSK won the world's first approval for Hibsago, a functional cure for chronic hepatitis B, in Japan. It also advanced its own mRNA flu vaccine to Phase III after positive mid-stage data. Both are new pipeline wins that could drive long-term growth and support the shares.

    Two separate pipeline successes show GSK's research is delivering new products.

▲4

GSK's cost cuts and pipeline push lift shares despite profit dip

  • £1.9bn savings drive and UK investment GSK launched a three-year £1.9bn cost-savings plan to fund late-stage drug trials and simplify the business, plus a £400m UK investment including a new R&D centre. Shares jumped 4.2% as investors welcomed the plan to protect profits while spending on new drugs.

    This is the main new event that directly moved the share price up and shows management's plan to fund growth.

  • Q2 profit beat and raised sales guidance GSK beat second-quarter profit expectations, with sales up 5% to over £8.4bn and core earnings per share up 9%. It raised full-year sales and operating profit guidance to the upper half of its range, though it lowered EPS guidance due to extra interest costs from the Nuvalent deal.

    The earnings beat and guidance raise are new and directly support the share price, while the EPS cut is a real counterweight.

  • AI drug discovery partnership and Cambridge R&D hub GSK expanded its AI drug discovery collaboration with Relation Therapeutics, worth up to $110m, and announced a new Cambridge R&D hub for over 1,000 scientists. These moves aim to speed up finding new drugs and strengthen GSK's long-term pipeline.

    This is a new strategic step that could improve future growth prospects, though the financial impact is longer-term.

  • Record UK lab space demand from GSK prelet GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus helped push UK lab space demand to a record high. This shows GSK is investing in research capacity, but high lab vacancies and slowing construction are a broader industry caution.

    It confirms GSK's commitment to UK R&D and signals demand for its facilities, a new positive signal for the company's growth plans.

July 2026
▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

Q2 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

June 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

Bristol-Myers Squibb Company (BMY)

Q3 2026
▲3▼1

Bristol-Myers Q3: Pipeline Wins, Financial Beat, But Competitive and Legal Risks Loom

  • Strong Q2 results and raised guidance Bristol reported Q2 revenue of about $13 billion and a 40% jump in earnings per share, prompting management to raise full-year revenue guidance to $49–50 billion. Analysts also increased their 2026 EPS estimates to $6.91.

    This shows the company's core financial performance and improved outlook, a key positive driver for the stock.

  • Pipeline and regulatory progress The FDA accepted mezigdomide for review, approved ZENBEXUS for multiple myeloma, and expanded Camzyos to treat pediatric patients. These advances strengthen Bristol's product lineup and help offset future patent losses.

    New drug approvals and expanded uses are direct growth catalysts that can drive future sales and investor confidence.

  • AI and infrastructure investments Bristol partnered with NVIDIA, Schrödinger, and Chai Discovery on AI-driven drug discovery, and opened a new San Diego hub and Houston plant. These investments aim to speed up research and expand manufacturing capacity.

    Long-term growth initiatives that could improve efficiency and innovation, supporting the stock's future potential.

  • Competitive and legal pressures Cytokinetics' Myqorzo threatens Camzyos, J&J's psoriasis pill challenges Sotyktu in China, and AstraZeneca merger talks collapsed. A $6.7B Celgene lawsuit revived, and CAR-T trials paused after Novartis deaths.

    These setbacks create uncertainty and potential revenue loss, weighing on the stock price.

September 2026
▲2▼2

BMY pipeline advances, but competition and safety concerns weigh

  • Pipeline and label expansion Zenbexus won FDA accelerated approval for relapsed multiple myeloma, Camzyos expanded to pediatric patients, and Arlo-cel met its Phase 2 endpoint, strengthening BMY's growth prospects.

    This is a key positive development that could drive future revenue and investor optimism.

  • Analyst EPS estimate raise Growth products now make up 56% of revenue, leading analysts to raise 2026 EPS estimates to $6.91 from $6.34, reflecting confidence in BMY's earnings power.

    This shows improved financial outlook and analyst confidence, which can positively impact the stock.

  • Competitive threat to Sotyktu J&J's oral psoriasis pill won Chinese approval, threatening Sotyktu in a market of over 8 million patients, potentially limiting BMY's growth in a key segment.

    This competitive pressure could hurt BMY's market share and revenue, a negative for the stock.

  • CAR-T trial pause Bristol paused CAR-T trials after Novartis deaths, raising regulatory and safety concerns that could delay development and pressure the stock.

    This introduces uncertainty and potential setbacks in a promising area, negatively impacting investor sentiment.

Latest
▲4

Bristol's Growth Portfolio Accelerates with New Drug Approvals and Strong Pipeline Data

  • Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

    Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

  • Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

    A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

  • Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

    Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

  • Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

    Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

▲3▼2

Bristol's Cancer Pipeline Advances, but Competition and Safety Fears Linger

  • Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

    This is a new drug approval that directly adds a future revenue driver for BMY.

  • J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

    New competitive threat in a key market that could slow BMY's psoriasis drug sales.

  • Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

    New clinical data that supports the durability and safety of a key growth drug.

  • CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

    New safety event that directly affects BMY's CAR-T development and investor risk perception.

  • Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

    New positive clinical trial result that advances a potential new therapy for BMY.

August 2026
▲2▼2

BMY beats on earnings, raises guidance, but merger talks collapse

  • Strong Q2 earnings and raised guidance Bristol-Myers Squibb reported Q2 revenue of about $13 billion, beating estimates, with earnings per share jumping 40% to $2.04. Management raised full-year guidance twice, ending at $49–50 billion, driven by Eliquis (+19%) and newer drugs like Camzyos and Reblozyl.

    This is the main positive force behind BMY's stock in August, showing better-than-expected financial performance and improved outlook.

  • FDA approves ZENBEXUS and AI partnerships expand The FDA approved ZENBEXUS for multiple myeloma, adding a new treatment to Bristol's portfolio. The company also expanded AI partnerships with Nvidia, Schrödinger, and Chai Discovery, and announced a $2.3 billion Houston plant, supporting long-term growth.

    These new developments strengthen BMY's pipeline and manufacturing, offering future revenue potential.

  • AstraZeneca merger talks collapse Reported merger talks with AstraZeneca fell apart, removing a potential takeover premium that had lifted BMY's stock. Without a merger, Bristol faces its patent cliff alone, increasing pressure to replace lost revenue from older drugs.

    This is a major negative event that removed a catalyst and leaves BMY more vulnerable to patent expirations.

  • Revived $6.7 billion Celgene lawsuit A $6.7 billion lawsuit related to the Celgene acquisition has been revived, adding legal and financial uncertainty. This could raise BMY's risk premium and pressure the stock as investors weigh potential liabilities.

    This new legal issue introduces uncertainty and potential financial burden, negatively impacting investor sentiment.

▲3▼1

Bristol Raises Outlook, Expands AI and Manufacturing Despite Legal and Competitive Risks

  • Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

    This is the most significant new positive catalyst, directly raising revenue and profit outlook.

  • Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

    This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

  • Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

    This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

  • Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

    This new legal development introduces a significant potential liability, a negative factor for the stock.

▲3▼1

Bristol's Q2 Beat and New Drug Approval Offset Failed Merger

  • Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

    This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

  • AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

    The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

  • FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

    This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

  • Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

    These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

▲2

Bristol Q2 Beat and AstraZeneca Merger Talk Lift BMY

  • Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

    This is the core fundamental news of the period and directly supports a higher valuation for BMY.

  • Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

    This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

  • Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

    It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

July 2026
▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

Q2 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

June 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

© 2026 MarketIVWhy